Over at Theranos, some big names are out, one notable name is staying put, and some others were accidentally outed.

On Thursday, the disgraced blood testing company announced that members of its distinguished yet puzzling "board of counselors" would be stepping down January 1. Those members include former Secretaries of State Henry Kissinger and George Shultz, former defense secretary William Perry, and former Senators Sam Nunn and Bill Frist. Also going is Riley Bechtel, chairman of the country’s largest construction and civil engineering company, who served on Theranos’ board of directors.

Notably absent from the list of high-profile departures is retired Marine Corps Gen. James “Mad Dog” Mattis. The four-star general, who joined Theranos’ board of directors in 2013, just so happens to also be President-elect Donald Trump’s nominee for defense secretary. Trump formally announced the nomination Tuesday evening.

While the other prominent figureheads never seemed particularly suited for the blood testing business during their time with the company, Mattis had proven his usefulness before joining as a director. In 2012, he pushed for the US Army to use Theranos’ equipment in the battlefield. The plan was nixed when the Army realized that Theranos' technology hadn’t obtained the necessary approvals from the Food and Drug Administration.

Nevertheless, Mattis has remained a strong ally. In a December 2015 statement to the Washington Post about the matter, Mattis said:

Theranos had demonstrated a commitment to investing in and developing technologies that can make a difference in people’s lives, including for the severely wounded and ill… I had quickly seen tremendous potential in the technologies Theranos develops, and I have the greatest respect for the company’s mission and integrity.

If Mattis is confirmed as secretary of defense, he will have to step down from Theranos.

In light of all of Theranos’ technological, regulatory, and personal scandals, lingering confidence in the company may be hard to understand. But leaked e-mails from Theranos to the company’s investors may partly explain the situation.

According to The Wall Street Journal, Theranos sent e-mails to investors in 2014 and 2015 saying that the company expected it would rake in $2 billion in revenue in 2016 and $505 million in net income. Theranos released those predictions despite looming problems with federal regulators and continued performance issues with its technology. The company has since shuttered its clinical labs and blood testing.

In addition to the generous financial situation Theranos forecasted, Walgreens alleged in a $140 million lawsuit that Theranos, its ex-partner, wildly overstated the state of its technology. For instance, Theranos claimed that the US government had already been using the technology prior to 2010, according to the lawsuit.

While the leaked investor e-mails further reveal the extent to which the company may have misled prominent figureheads, investors, and partners alike, one provided something journalists have long sought: names of private investors. In a clear blunder, the company forgot to BCC 132 investors on one update e-mail sent Thursday. The e-mail, leaked to the WSJ, lists out all of their addresses. Recipients included representatives of the Walton family (which owns Walmart), representatives of New England Patriots owner Robert Kraft’s Kraft Group, and an executive of Mexico’s Grupo Financiero Inbursa SAB founded by billionaire Carlos Slim (one of the richest people in the world), as well as family members of Elizabeth Holmes, Theranos’ CEO and founder.

The WSJ had previously outed several other private investors, including Rupert Murdoch, executive chairman of News Corp and 21st Century Fox Inc., and Oracle co-founder Larry Ellison.

Theranos and the recipients declined to comment or couldn’t be reached by the WSJ. Theranos faces several lawsuits from investors and is under federal criminal investigation for allegedly misleading investors.